1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Digital Landscape: Type 2 Diabetes

Digital Landscape: Type 2 Diabetes

  • August 2018
  • 142 pages
  • ID: 5500246
In this report:
BRAND SITES LAUNCHED FOR NEW FDA-APPROVED PRODUCTS IN 2017, INCLUDING MERCK'S STEGLATRO AND NOVO NORDISK'S OZEMPIC; ASTRAZENECA UPDATED MESSAGING ON FARXIGA SITES AND DIGITAL DISPLAY ADS; IT ALSO REMOVED BYDUREON PATIENT SUPPORT FEATURES IN LATE 2017, AND ADDED INFORMATION ABOUT THE NEW BYDUREON DEVICE TO BRAND SITES.

Summary

Table of Contents

Search Inside

Digital Landscape: Type 2 Diabetes

Brief

"Digital Landscape: Type 2 Diabetes", examines digital activities undertaken by pharmaindustry in support of therapies for Type 2 Diabetes (T2D).

- The study includes digital activities directed towards patients and/or HCPs

- The geographic scope of the report is the United States, EUCAN (Canada (CA) and the 5EU countries - UK, Germany (DE), France (FR), Italy (IT) & Spain (ES))

- The principal focus of the report is DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists

Key Findings

- US Patients: Good support for US T2D patients across channels, particularly from Novo Nordisk, Merck, BI / Lilly and AstraZeneca. Updates seen in the branded space in 2017, with activity detected in the T2D / CV unbranded space from Novo Nordisk and BI / Lilly. Global lack of diabetes-specific mobile apps from pharma, however Novo Nordisk and Roche were active in 2017. Growing number of partnerships between pharma and technology companies could lead to future innovation in diabetes management.

- US HCPs: Limited support for US HCPs beyond brand sites, with activity seen from various companies across the branded landscape in 2017. J&J offers the best unbranded and social media support to HCPs. Pharma-sponsored mobile app support is limited, with a number of companies sponsoring non-pharma offerings, including AstraZeneca and BI / Lilly. Novo Nordisk entered the HCP mobile app space in late 2017.

- EUCAN Patients: Lilly offers strong branded support for Trulicity patients across EU with multi-country, local-language sites and a mobile app. Sanofi has the most unbranded sites across EUCAN, and has the strongest examples of social media support in Canada (CA). No pharma-sponsored social media accounts detected in Germany (DE) or the UK.

- EUCAN HCPs: Sparse digital landscape for EUCAN HCPs. Lilly and Sanofi have brand content on corporate diabetes sites in Germany (DE) and the UK. Few HCP-directed unbranded sites were detected from pharma, with Sanofi's offering in France (FR) providing the best support features. Limited social media activity beyond corporate accounts, and all pharma-sponsored mobile apps were detected in Spain (ES).

- Companies Mentioned: Novo Nordisk, Merck / MSD, Sanofi, AstraZeneca, BoehringerIngelheim, Eli Lilly, J&J / Janssen, Takeda, GSK, Roche, Bayer.

Overview

- This business report examines digital activities undertaken by Pharma in support of therapies for Type 2 Diabetes (T2D), with a focus on DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists.

- The analysis includes digital activities directed towards patients and/or HCPs, containing branded websites, unbranded disease awareness initiatives, social media and mobile apps.

- The market research is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also comprises analysis of data licensed from third parties e.g. website traffic, search engine optimization, digital display advertising, mobile app downloads, and social media interaction.

- The geographic scope of the report is the United States, Canada (CA) and the 5EU (UK, Germany (DE), France (FR), Italy (IT) & Spain (ES)), with EUCAN used as an abbreviation for Europe (EU) and Canada (CA) throughout.

- This industry report includes the research period from January - December 2017.

Great reasons to purchase

- Our Digital Landscape report offers an analysis of Pharma multichannel activity in the digital T2D space, and can assist our Pharma clients derive value in a number of ways:

- Competitive Intelligence: Track and compare main competitor activity across channels and distinguish top trends in T2D

- Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and analyze possibilities for novel digital campaigns

- Support additional brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess plausible gaps and alternatives for pipeline brands

- Business Development & Licensing: Assess topics and forecasts shaping digital health in T2D and beyond, and learn about main patient and physician online activities in T2D.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2018

  • $ 2000
  • October 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal ...

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018SummaryIslet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide ...

Wearable Injectors Market: Global Forecast until 2023

Wearable Injectors Market: Global Forecast until 2023

  • $ 5650
  • October 2018

The wearable injectors market is projected to grow at a CAGR of 11.1% during the forecast period.The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from an estimated USD ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on